This phase II study is investigating how safe and effective it is to administer heated (42 degrees Celsius) versus normal temperature (37 degrees Celsius) chemotherapy during surgery for people with epithelial ovarian, fallopian tube or peritoneal cancer.
This trial is treating patients with epithelial ovarian, fallopian tube or peritoneal cancer.
This is a systemic therapy and surgical trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
The safety of hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer (HYNOVA).
Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Other Non-Commercial Sponsor
University of Sydney
Eligible participants will receive cisplatin chemotherapy administered to the abdominal cavity through a catheter for 90 minutes during surgery. Participants will be randomly allocated to either the hyperthermic arm, who will receive the chemotherapy drug heated to 42 degrees Celsius, or the normothermic arm, who will receive the drug at normal body temperature of 37 degrees Celsius.
Recruiting Hospitals Read More